About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
Submit
May 9, 2023
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
April 12, 2023
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
April 11, 2023
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
March 6, 2023
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
February 28, 2023
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
< previous
1
2
3
4
5
next >
